Abstract 55P
Background
Uterine sarcoma make up about 1–2% of all malignant gynecological tumors and have an aggressive clinical course with a high relapse-rate. Because of it, patients contribute maximal comprehensive treatment. The rationale of hormonal therapy is generally extrapolated from data of hormone-sensitive breast cancer.
Methods
Among 129 uterine sarcoma patients, stages IB – IIA (T1b-2aNxM0), in 70 (54,3 %) of them there were detected expression of hormone receptors. All the patients underwent surgery, radiation therapy and chemotherapy. Hormone therapy was administered in 42 patients (1 st group) with expression of ERPR-receptors in tumor tissue, and was not prescribed for 28 patients of the (2nd group) without it. The expression of hormone receptors was conducted by immune-hystochemical analyze. The follow-up of these patients was 6–36 months, its median — 22 months, the average duration — 22.0 ± 2.8 months.
Results
Expression of PR was detected in 88,6% (62 of 70 patients), among them: in 88,5% of LMS patients, in 100,0% of ESS patients and in 50% of NDS patients. The co-expression of ER/PR was determined in 81,0% of cases. The relapse was detected in 16,7% patients, among them were in 20,0% of LMS patients and 0% of ESS patients, in comparison to 42,9% of those patients, who haven’t obtained adjuvant hormonetherapy.
Conclusions
It was confirmed that the hormone receptors are important targets of therapy in uterine sarcoma patients, and was found that the adjuvant hormone therapy in hormone-positive patients with leiomyosarcoma contributes to 90% two-year recurrence-free survival.
Clinical trial identification
Editorial acknowledgement
This academic study was approved by National academy of medical sciences in Ukraine, with support of UkrGOG (Ukrainian Group of Oncologists and Gynecological oncologist).
Legal entity responsible for the study
National Academy of Medical Sciences in Ukraine, with support of UkrGOG (Ukrainian Group of Oncologists and Gynecological oncologist).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.